Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

198.94 +4.19 (+2.15%)
Streaming Delayed Price Updated: 10:19 AM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
From Natera, Inc.
Via Business Wire
News headline image
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Here's How Much $100 Invested In Natera 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
1 Volatile Stock to Own for Decades and 2 to Brush Off
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Preview: Natera's Earnings ↗
 
Via Benzinga
News headline image
Peering Into Natera's Recent Short Interest ↗
 
Via Benzinga
News headline image
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons We Love Natera (NTRA)
Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 5% to $170 per share while the index has gained 1.1%. 
Via StockStory
Topics Government Stocks
News headline image
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue... 
Via StockStory
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Natera Announces Medicare Coverage for Signatera™ Genome
From Natera, Inc.
Via Business Wire
News headline image
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
From Natera, Inc.
Via Business Wire
News headline image
2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary Of
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
News headline image
3 Mid-Cap Stocks Worth Your Attention
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses... 
Via StockStory
News headline image
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
8 Analysts Have This To Say About Natera ↗
 
Via Benzinga
News headline image
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98... 
Via StockStory
News headline image
Natera Reports First Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
From Natera, Inc.
Via Business Wire
News headline image
What To Expect From Natera’s (NTRA) Q1 Earnings
Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its First Quarter Results on May 8, 2025
From Natera, Inc.
Via Business Wire
News headline image
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
From Natera, Inc.
Via Business Wire
News headline image
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.